Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1995 Jan;39(1):150–154. doi: 10.1128/aac.39.1.150

Modification of immune response in mice by ciprofloxacin.

M Jimenez-Valera 1, A Sampedro 1, E Moreno 1, A Ruiz-Bravo 1
PMCID: PMC162501  PMID: 7695298

Abstract

Some studies have suggested that the addition of ciprofloxacin to in vitro cultures of mitogen-stimulated lymphocytes exerts inhibitory effects on cell cycle progression and immunoglobulin (Ig) secretion. We tested the effects of this drug on some immunity parameters in BALB/c mice. Mice treated intraperitoneally with ciprofloxacin (10 mg/kg of body weight per day) for 3 consecutive days and immunized with sheep erythrocytes 24 h after the last injection showed significant suppression of hemolytic IgG-forming cells, whereas the response of IgM-forming cells remained unchanged. When treatment lasted 7 days the response of antibody-forming cells was not modified. When the 3-day treatment was started at 24 h after immunization with sheep erythrocytes, the response of IgM-forming cells was increased, whereas the response of IgG-forming cells was suppressed. Delayed-type hypersensitivity to sheep erythrocytes was significantly suppressed in animals that received the 3-day treatment with ciprofloxacin and were immunized subcutaneously 24 h after the last injection. In vitro proliferation of lymphocytes from ciprofloxacin-treated mice in response to either lipopolysaccharide or concanavalin A was also suppressed. Leukopenia and an increase in the level of granulocyte-macrophage colony-forming cells in bone marrow were also observed in ciprofloxacin-treated mice. These results, together with those from other reports, suggest that modification of the biological responses by ciprofloxacin is a complex phenomenon that may be influenced by several factors.

Full Text

The Full Text of this article is available as a PDF (164.3 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Athanassiades T. J. Adjuvant effect of Bordetella pertussis vaccine to sheep erythrocytes in mice: enhancement of cell-mediated immunity by subcutaneous administration of adjuvant and antigen. Infect Immun. 1977 Nov;18(2):416–423. doi: 10.1128/iai.18.2.416-423.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Easmon C. S., Crane J. P. Uptake of ciprofloxacin by human neutrophils. J Antimicrob Chemother. 1985 Jul;16(1):67–73. doi: 10.1093/jac/16.1.67. [DOI] [PubMed] [Google Scholar]
  3. Forsgren A., Bergh A. K., Brandt M., Hansson G. Quinolones affect thymidine incorporation into the DNA of human lymphocytes. Antimicrob Agents Chemother. 1986 Mar;29(3):506–508. doi: 10.1128/aac.29.3.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Forsgren A., Bredberg A., Pardee A. B., Schlossman S. F., Tedder T. F. Effects of ciprofloxacin on eucaryotic pyrimidine nucleotide biosynthesis and cell growth. Antimicrob Agents Chemother. 1987 May;31(5):774–779. doi: 10.1128/aac.31.5.774. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Forsgren A., Schlossman S. F., Tedder T. F. 4-Quinolone drugs affect cell cycle progression and function of human lymphocytes in vitro. Antimicrob Agents Chemother. 1987 May;31(5):768–773. doi: 10.1128/aac.31.5.768. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Gootz T. D., Barrett J. F., Sutcliffe J. A. Inhibitory effects of quinolone antibacterial agents on eucaryotic topoisomerases and related test systems. Antimicrob Agents Chemother. 1990 Jan;34(1):8–12. doi: 10.1128/aac.34.1.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983 Dec 16;65(1-2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  8. Pallavicini F., Antinori A., Federico G., Fantoni M., Nervo P. Influence of two quinolones, ofloxacin and pefloxacin, on human myelopoiesis in vitro. Antimicrob Agents Chemother. 1989 Jan;33(1):122–123. doi: 10.1128/aac.33.1.122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Parker D. C. T cell-dependent B cell activation. Annu Rev Immunol. 1993;11:331–360. doi: 10.1146/annurev.iy.11.040193.001555. [DOI] [PubMed] [Google Scholar]
  10. Ramirez-Ronda C. H., Saavedra S., Rivera-Vázquez C. R. Comparative, double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections. Am J Med. 1987 Apr 27;82(4A):220–223. [PubMed] [Google Scholar]
  11. Roszkowski W., Ko H. L., Roszkowski K., Ciborowski P., Jeljaszewicz J., Pulverer G. Effects of ciprofloxacin on the humoral and cellular immune responses in Balb/c-mice. Zentralbl Bakteriol Mikrobiol Hyg A. 1986 Sep;262(3):396–402. doi: 10.1016/s0176-6724(86)80013-x. [DOI] [PubMed] [Google Scholar]
  12. Traub W. H. Intraphagocytic bactericidal activity of bacterial DNA gyrase inhibitors against Serratia marcescens. Chemotherapy. 1984;30(6):379–386. doi: 10.1159/000238297. [DOI] [PubMed] [Google Scholar]
  13. Wolfson J. S., Hooper D. C. The fluoroquinolones: structures, mechanisms of action and resistance, and spectra of activity in vitro. Antimicrob Agents Chemother. 1985 Oct;28(4):581–586. doi: 10.1128/aac.28.4.581. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES